Prana Biotechnology Says PBT2 Recommended For Orphan Designation In Europe

(RTTNews) - Prana Biotechnology (PBT.AX, PRAN) said the European Medicines Agency's Committee for Orphan Medicinal Products or COMP has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission.

Following finalization of relevant documents, the European Medicines Agency forwards the opinion to the European Commission for its decision on the designation.

Orphan designation is granted by the European Commission to encourage the development of medicines to treat rare diseases, which are defined as life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in Europe.